top of page

Investor Relation

FILINGS AND DISCLOSURE

SEC Filings

FORM TYPE
RECEIVED
PERIOD END DATE
HTML
XLS
8-K
15/10/2024
09/10/2024
HTML
XLS
8-K
10/10/2024
04/10/2024
HTML
XLS
8-K
25/09/2024
23/09/2024
HTML
XLS
8-K
18/09/2024
14/09/2024
HTML
XLS
DEF 14A
16/09/2024
04/10/2024
HTML
XLS
8-K
12/09/2024
11/09/2024
HTML
XLS
PRE 14A
06/09/2024
06/09/2024
HTML
XLS
8-K
05/09/2024
04/09/2024
HTML
XLS
8-K
28/08/2024
27/08/2024
HTML
XLS
8-K
26/08/2024
26/08/2024
HTML
XLS
Page 1 of 10

Board Diversity Matrix (as of March 26, 2024)

Country of Principal Executive Offices
Malaysia
Disclosure Prohibited under Home Country Law
No
Foreign Private Issuer
No
Total Number of Directors
5
Part I: Gender Identity
Male
Female
Non-Binary
Gender Undisclosed
Directors
5
0
0
0
Part II: Demographic Background
Did Not Disclose Demographic Background
0
LGBTQ+
0
Underrepresented Individual in Home Country Jurisdiction
1

INSIDER DISCLOSURE

Disclosure & News

Code of Ethics and Business Conduct

We have adopted a code of ethics and business conduct applicable to our directors, officers and employees. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions.

Click the pages below or click here for the details.

For further information on investor relation, please email to ir@bionexuslab.com

bottom of page